Publications

1. GVS assessment of hydrocortisone (Alkindi®) for the treatment of adrenal insufficiency

   The National Health Care Institute has completed its assessment whether hydrocortisone (Alkindi®) can be included in the ...

   Report | 10-12-2019

2. Metreleptin (Myalepta®) for treatment of lipodystrophy

   Zorginstituut Nederland has completed its assessment whether metreleptin (Myalepta®) for treatment of lipodystrophy can be ...

   Report | 21-10-2019

3. GVS assessment of extension of further conditions for GLP-1ra

   The minister for Medical Care asked Zorginstituut Nederland to extend the further conditions for the glucagon-like peptide 1 ...

   Report | 26-09-2019

4. Ciclosporin (Ikervis®) for the treatment of severe keratitis in adult patients with the dry eye syndrome

   The National Health Care Institute has completed its assessment whether ciclosporin (Ikervis®) for the treatment of severe ...

   Report | 18-09-2019

5. Dabrafenib/trametinib (Tafinlar®/Mekinist®) for the adjuvant treatment of adult patients with stage III melanoma

   The National Health Care Institute has completed its assessment of dabrafenib (Tafinlar®) in combination with trametinib ...

   Report | 28-08-2019

6. GVS assessment of fampridine (Fampyra®) for use in a subgroup of MS patients

   The National Health Care Institute has completed its assessment whether fampridine (Fampyra®) can be included in the Medication ...

   Report | 06-08-2019

7. Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) for the treatment of adults infected with HIV-1

   The National Health Care Institute has completed its assessment whether Delstrigo® (doravirine/lamivudine/tenofovir disoproxil ...

   Report | 27-06-2019

8. Doravirine (Pifeltro®) for the treatment of adults infected with HIV-1

   The National Health Care Institute has completed its assessment whether Pifeltro® (doravirine) can be included in the Medication ...

   Report | 27-06-2019

9. Erenumab (Aimovig®) for the prophylaxis of adults with migraine

   The National Health Care Institute has completed its assessment whether erenumab (Aimovig®) for the prophylaxis of adults with ...

   Report | 27-06-2019

10. Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma

    The National Health Care Institute has completed its assessment whether ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line ...

    Report | 29-05-2019